We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Moderna Inc | NASDAQ:MRNA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.23 | -0.18% | 125.36 | 116.45 | 129.00 | 126.3843 | 122.01 | 125.06 | 4,513,134 | 05:00:04 |
By Josh Beckerman
Johnson & Johnson said new study results provide "real world evidence" that its Covid-19 vaccine "demonstrates durable protection against breakthrough Infection, hospitalization, and intensive care unit admission in the United States."
"While these are rapidly evolving data, we are seeing vaccine effectiveness against COVID-19-related hospitalization of approximately 80 percent from a single shot of the Johnson & Johnson vaccine, and this level of protection holds steady across the length of time studied thus far -- up to six months," the company said.
J&J said the new study posted on medRxiv "comprehensively looked at the durability profiles for all three vaccines authorized or approved in the U.S. using the same methodology across three outcomes of interest: COVID-19 breakthrough infections, hospitalizations, and ICU admissions."
Last week, the company said its booster vaccine for Covid-19 was 85% effective against hospitalization in a study conducted in South Africa after the Omicron variant became dominant.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 06, 2022 17:17 ET (22:17 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Moderna Chart |
1 Month Moderna Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions